Organigram Global Inc.
OGI Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Organigram Global Inc. had $185M of revenue in fiscal 2025. Over five years, revenue changed +23.5% a year on average.
- Its operating margin was −5.9%: of every 100 in sales, about −6 is left after running the business.
- Organigram Global Inc. lost $17.7M in fiscal 2025.
- Free cash flow was −$17.6M in fiscal 2025, −9.5% of revenue.
- Organigram Global Inc. has $60.0M more cash than debt.
Market cap
—
P/E
—
Revenue
$185M
Net income
−$17.7M
Free cash flow
−$17.6M
Operating margin
−5.9%
Organigram Global Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−9.6%
No. It lost money last year.
Does profit turn into cash?
−9.5%
No. It spent more cash than it brought in.
What Organigram Global Inc. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 40-F · Dec 16, 2025
- Legal name
- ORGANIGRAM GLOBAL INC.
- CIK
- 0001620737
Organigram Global Inc. · OGI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY20 | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $64.5M | $62.4M | $115M | — | $185M |
| Revenue growth | 6.3% | −3.3% | 83.8% | — | — |
| Gross margin | −65.1% | −35.9% | 21.7% | — | 34.8% |
| Operating margin | −167.6% | −116.0% | −29.6% | — | −5.9% |
| Net income | −$101M | −$103M | −$11.2M | — | −$17.7M |
| Net margin | −156.9% | −165.1% | −9.8% | — | −9.6% |
| Diluted EPS | −$0.59 | −$0.40 | −$0.14 | — | −$0.14 |
| Cash | |||||
| Cash from operations | −$33.5M | −$22.5M | −$28.5M | — | −$5.4M |
| Capital expenditure | $57.4M | $9.3M | $38.3M | — | $12.2M |
| Free cash flow | −$90.9M | −$31.8M | −$66.8M | — | −$17.6M |
| FCF margin | −141.0% | −51.0% | −58.3% | — | −9.5% |
| Share count change | 17.5% | 43.8% | −69.8% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | — | — | — | $98.1M | $60.0M |
| Debt incl. finance leases | $88.2M | $0.2M | $0.2M | $0.0M | $0.0M |
| Shareholders' equity | $229M | $381M | $388M | $226M | $251M |
| Current ratio | 5.9x | 9.9x | 4.0x | 4.9x | 2.3x |
| Interest coverage | −24.2x | −31.0x | −100.6x | — | — |
| Returns and quality | |||||
| Return on capital | — | — | — | — | −4.5% |
| Return on equity | −42.6% | −33.7% | −2.9% | — | −7.4% |
| Return on tangible equity | −44.4% | −28.0% | −3.3% | — | −9.9% |
| Piotroski F-score | 3 | 5 | 5 | — | — |
| Altman Z'' | 1.2 | 6.8 | 7.5 | — | −0.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Organigram Global Inc. · OGI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001620737). Data updated October 24, 2026. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.